Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Ruxolitinib in Pediatric GVHD
NCT05121142Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Oct 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD) and chronic graft-versus-host disease (cGVHD) (3 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Maximum Plasma Concentration (Cmax) at 6 months and Phosphorylation of STAT5 on lymphocytes. Started Oct 2021; status: completed.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05121142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121142.